Restem
Chemicals & Related Products · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
355 E Rincon St Ste 125, Corona, Califor...Website
www.restem.comRevenue
$7.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Restem
Restem is a biotechnology company focused on advancing immune health through innovative cell-based therapeutics aimed at treating inflammatory-driven diseases. With a proprietary platform utilizing Umbilical Cord Lining Modified Progenitor Cells (UMPCs) and Activated Natural Killer (NK) Cells, Restem aims to modulate immune responses and support tissue repair. The company has developed a strong intellectual property portfolio and manufacturing capabilities to produce off-the-shelf cellular therapeutics, with ongoing clinical trials for conditions such as Idiopathic Inflammatory Myopathy and Rheumatoid Arthritis. Targeting a global market of over 780 million people suffering from autoimmune diseases, Restem is committed to transforming cutting-edge science into life-changing treatments.Explore more
Restem Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Restem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Restem
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Restem is spiking on competitors!
Check if Restem has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Restem recently announced quarterly report
Funding: Get notified immidiatlly once Restem has new funding data
Product Launch: Get notified when Restem launches new products
Click to see if Restem had a recent Job posting/layoffs
Restem, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Restem
Find 2 more new buyers
Compare Similar Companies to Restem
Compare insights from companies similar to Restem, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Restem is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Restem is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Restem.
Restem Tech Stack
A closer look at the technologies used by Restem
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Person-Based
Brian Pla, Chief Commercial Officer (Cco), appeared on a podcast called "Skin Anarchy" on 10/24/2025. Topics discussed include Exosomes, Skin Regeneration, Biotech.
Events, Podcast
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Person-Based
Brian Pla, Founder and CEO, appeared on a podcast called "Boundless Life" on 03/15/2025. Topics discussed include Exosomes, regenerative medicine, biocosmetics, precision medicine.
Events, Podcast
Project
Spending/Investment
Restem News & Media
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
MIAMI, Feb. 03, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced it had dosed the first patient in the Phase 2/3 IIMPACT trial of Restem-L, the Company’s, investigational umbilical lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as idiopathic inflRESTEM Provides Corporate Update and Announces Strategic Priorities for 2026
MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today provided a corporate update and announced its strategic priorities for 2026.RESTEM to Present Company Overview in Biotech Showcase 2026
MIAMI, Dec. 22, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its participation in Biotech Showcase 2026, to be held on January 12-14, 2026, in San Francisco, California.RESTEM to Participate in the 15th LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference in January 2026
MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its management team will participate in the 15th LifeSci Partners Corporate Access event taking place January 12-14, 2026, in San Francisco, California.
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Restem
Sign Up For FreeTo access detailed company insights
Restem is a biotechnology company focused on advancing immune health through innovative cell-based therapeutics aimed at treating inflammatory-driven diseases. With a proprietary platform utilizing Umbilical Cord Lining Modified Progenitor Cells (UMPCs) and Activated Natural Killer (NK) Cells, Restem aims to modulate immune responses and support ti... Read More
